news
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
List view / Grid view
Lymphoma
Filter the results
news
NICE recommends Adcetris (brentuximab vedotin) for treatment of rare lymphoma
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
news
Dose-adjusted chemotherapy regimen effective in Burkitt lymphoma trial
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
news
EMA begins safety review of ifosfamide cancer medicines
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
news
Ten drugs in pre-registration likely to be blockbusters by 2025, finds report
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
news
Lenalidomide recommended for use with rituximab by NICE
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
news
Scientists share promising results of BET and EZH2 inhibitors for lymphoma
Researchers at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris have presented new epigenetics compounds that show early activity in lymphoma patients.
news
Karus Therapeutics doses first lymphoma patients in Phase I KA2237 clinical study
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110β and p110δ. Inhibiting these two isoforms combines an immunotherapeutic response...
news
Takeda and Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma
1 August 2016 | By Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.
Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement...
news
Cancer treatment receives EU drug designations
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
With the EU orhpan drug designations, Cell Medica can now obtain regulatory and financial incentives for developing and marketing CMD-003 as a cancer...
news
Ibrutinib shown to be superior to chlorambucil in trial
7 December 2015 | By Victoria White
Janssen-Cilag International NV has announced data from the Phase 3 RESONATE-2 (PCYC-1115) trial that show ibrutinib (Imbruvica) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older.
news
European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
news
European Commission approves IMBRUVICA in two forms of blood cancer
20 October 2014 | By Janssen
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.